ID   BXB_CLOBO               Reviewed;        1291 AA.
AC   P10844; P10843;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   03-AUG-2022, entry version 183.
DE   RecName: Full=Botulinum neurotoxin type B;
DE            Short=BoNT/B;
DE   AltName: Full=Bontoxilysin-B;
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin B light chain;
DE              Short=LC;
DE              EC=3.4.24.69 {ECO:0000269|PubMed:1331807};
DE   Contains:
DE     RecName: Full=Botulinum neurotoxin B heavy chain;
DE              Short=HC;
DE   Flags: Precursor;
GN   Name=botB {ECO:0000303|PubMed:1514783};
OS   Clostridium botulinum.
OC   Bacteria; Firmicutes; Clostridia; Eubacteriales; Clostridiaceae;
OC   Clostridium.
OX   NCBI_TaxID=1491;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Danish / Type B;
RX   PubMed=1514783; DOI=10.1128/aem.58.8.2345-2354.1992;
RA   Whelan S.M., Elmore M.J., Bodsworth N.J., Brehm J.K., Atkinson T.,
RA   Minton N.P.;
RT   "Molecular cloning of the Clostridium botulinum structural gene encoding
RT   the type B neurotoxin and determination of its entire nucleotide
RT   sequence.";
RL   Appl. Environ. Microbiol. 58:2345-2354(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-246.
RC   STRAIN=NCTC 7273 / Type B;
RA   Szabo E.A., Pemberton J.M., Desmarchelier P.M.;
RL   Submitted (APR-1992) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 634-994.
RC   STRAIN=NCTC 7273 / Type B;
RX   PubMed=8408542; DOI=10.1128/jcm.31.9.2255-2262.1993;
RA   Campbell K.D., Collins M.D., East A.K.;
RT   "Gene probes for identification of the botulinal neurotoxin gene and
RT   specific identification of neurotoxin types B, E, and F.";
RL   J. Clin. Microbiol. 31:2255-2262(1993).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-45 AND 442-467, SUBUNIT, SUBCELLULAR LOCATION, AND
RP   DISULFIDE BOND.
RC   STRAIN=B-657 / Type B;
RX   PubMed=3139097; DOI=10.1016/0300-9084(88)90111-3;
RA   Dasgupta B.R., Datta A.;
RT   "Botulinum neurotoxin type B (strain 657): partial sequence and similarity
RT   with tetanus toxin.";
RL   Biochimie 70:811-817(1988).
RN   [5]
RP   RELEASED AS SINGLE CHAIN.
RC   STRAIN=Okra / Type B1;
RX   PubMed=4030755; DOI=10.1016/s0021-9258(19)85105-0;
RA   Sathyamoorthy V., DasGupta B.R.;
RT   "Separation, purification, partial characterization and comparison of the
RT   heavy and light chains of botulinum neurotoxin types A, B, and E.";
RL   J. Biol. Chem. 260:10461-10466(1985).
RN   [6]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM NEUROTOXIN B HEAVY
RP   CHAIN), AND DOMAIN.
RC   STRAIN=Type B;
RX   PubMed=3856850; DOI=10.1073/pnas.82.6.1692;
RA   Hoch D.H., Romero-Mira M., Ehrlich B.E., Finkelstein A., DasGupta B.R.,
RA   Simpson L.L.;
RT   "Channels formed by botulinum, tetanus, and diphtheria toxins in planar
RT   lipid bilayers: relevance to translocation of proteins across membranes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1692-1696(1985).
RN   [7]
RP   IDENTIFICATION AS A ZINC-BINDING PROTEIN, AND COFACTOR.
RC   STRAIN=Type B;
RX   PubMed=1429690; DOI=10.1016/s0021-9258(18)35863-0;
RA   Schiavo G., Rossetto O., Santucci A., Dasgupta B.R., Montecucco C.;
RT   "Botulinum neurotoxins are zinc proteins.";
RL   J. Biol. Chem. 267:23479-23483(1992).
RN   [8]
RP   HOST RANGE, AND EPIDEMIOLOGY.
RX   PubMed=1431246; DOI=10.1093/infdis/166.6.1281;
RA   Woodruff B.A., Griffin P.M., McCroskey L.M., Smart J.F., Wainwright R.B.,
RA   Bryant R.G., Hutwagner L.C., Hatheway C.L.;
RT   "Clinical and laboratory comparison of botulism from toxin types A, B, and
RT   E in the United States, 1975-1988.";
RL   J. Infect. Dis. 166:1281-1286(1992).
RN   [9]
RP   FUNCTION (BOTULINUM NEUROTOXIN B LIGHT CHAIN), IDENTIFICATION OF SUBSTRATE,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND SUBCELLULAR LOCATION
RP   (BOTULINUM NEUROTOXIN B LIGHT CHAIN).
RC   STRAIN=Type B;
RX   PubMed=1331807; DOI=10.1038/359832a0;
RA   Schiavo G., Benfenati F., Poulain B., Rossetto O., de Laureto P.P.,
RA   Dasgupta B.R., Montecucco C.;
RT   "Tetanus and botulinum-B neurotoxins block neurotransmitter release by
RT   proteolytic cleavage of synaptobrevin.";
RL   Nature 359:832-835(1992).
RN   [10]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B), AND SUBSTRATE SPECIFICITY.
RX   PubMed=7803399; DOI=10.1021/bi00255a017;
RA   Foran P., Shone C.C., Dolly J.O.;
RT   "Differences in the protease activities of tetanus and botulinum B toxins
RT   revealed by the cleavage of vesicle-associated membrane protein and various
RT   sized fragments.";
RL   Biochemistry 33:15365-15374(1994).
RN   [11]
RP   IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE B), INTERACTION
RP   WITH HOST SYT1, AND SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN B LIGHT
RP   CHAIN).
RC   STRAIN=Type B;
RX   PubMed=8144634; DOI=10.1016/s0021-9258(17)34087-5;
RA   Nishiki T., Kamata Y., Nemoto Y., Omori A., Ito T., Takahashi M.,
RA   Kozaki S.;
RT   "Identification of protein receptor for Clostridium botulinum type B
RT   neurotoxin in rat brain synaptosomes.";
RL   J. Biol. Chem. 269:10498-10503(1994).
RN   [12]
RP   FUNCTION (BOTULINUM NEUROTOXIN B HEAVY CHAIN), AND LIPID-BINDING.
RC   STRAIN=B600 / Type B;
RX   PubMed=10413679; DOI=10.1242/jcs.112.16.2715;
RA   Lalli G., Herreros J., Osborne S.L., Montecucco C., Rossetto O.,
RA   Schiavo G.;
RT   "Functional characterisation of tetanus and botulinum neurotoxins binding
RT   domains.";
RL   J. Cell Sci. 112:2715-2724(1999).
RN   [13]
RP   RETRACTED PAPER.
RX   PubMed=10932255; DOI=10.1038/77997;
RA   Hanson M.A., Stevens R.C.;
RT   "Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type
RT   B at 2.0 A resolution.";
RL   Nat. Struct. Biol. 7:687-692(2000).
RN   [14]
RP   RETRACTION NOTICE OF PUBMED:10932255.
RX   PubMed=19578378; DOI=10.1038/nsmb0709-795;
RA   Hanson M.A., Stevens R.C.;
RT   "Retraction: Cocrystal structure of synaptobrevin-II bound to botulinum
RT   neurotoxin type B at 2.0 A resolution.";
RL   Nat. Struct. Mol. Biol. 16:795-795(2009).
RN   [15]
RP   FUNCTION, IDENTIFICATION OF HOST RECEPTOR (BOTULINUM NEUROTOXIN TYPE B AND
RP   BOTULINUM NEUROTOXIN B HEAVY CHAIN), INTERACTION WITH HOST SYT1 AND SYT2,
RP   AND SUBCELLULAR LOCATION (BOTULINUM NEUROTOXIN TYPE B).
RC   STRAIN=Type B;
RX   PubMed=14504267; DOI=10.1083/jcb.200305098;
RA   Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A.,
RA   Chapman E.R.;
RT   "Synaptotagmins I and II mediate entry of botulinum neurotoxin B into
RT   cells.";
RL   J. Cell Biol. 162:1293-1303(2003).
RN   [16]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM NEUROTOXIN B HEAVY
RP   CHAIN), AND INTERACTION WITH HOST SYT1 AND SYT2.
RC   STRAIN=Type B;
RX   PubMed=15123599; DOI=10.1074/jbc.m403945200;
RA   Rummel A., Karnath T., Henke T., Bigalke H., Binz T.;
RT   "Synaptotagmins I and II act as nerve cell receptors for botulinum
RT   neurotoxin G.";
RL   J. Biol. Chem. 279:30865-30870(2004).
RN   [17]
RP   FUNCTION, GANGLIOSIDE-BINDING (BOTULINUM NEUROTOXIN A HEAVY CHAIN), AND
RP   MUTAGENESIS OF GLU-1189; GLU-1190; HIS-1241; SER-1260; TRP-1262 AND
RP   TYR-1263.
RC   STRAIN=Okra / Type B1;
RX   PubMed=14731268; DOI=10.1046/j.1365-2958.2003.03872.x;
RA   Rummel A., Mahrhold S., Bigalke H., Binz T.;
RT   "The HCC-domain of botulinum neurotoxins A and B exhibits a singular
RT   ganglioside binding site displaying serotype specific carbohydrate
RT   interaction.";
RL   Mol. Microbiol. 51:631-643(2004).
RN   [18]
RP   DISCUSSION OF BELT FUNCTION, AND DOMAIN.
RX   PubMed=17907800; DOI=10.1371/journal.ppat.0030113;
RA   Brunger A.T., Breidenbach M.A., Jin R., Fischer A., Santos J.S., Montal M.;
RT   "Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for
RT   the light chain.";
RL   PLoS Pathog. 3:1191-1194(2007).
RN   [19]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM NEUROTOXIN B HEAVY
RP   CHAIN), INTERACTION WITH HOST SYT1 AND SYT2, AND MUTAGENESIS OF VAL-1118;
RP   TYR-1183; GLU-1191; LYS-1192 AND TRP-1262.
RC   STRAIN=Type B;
RX   PubMed=17185412; DOI=10.1073/pnas.0609713104;
RA   Rummel A., Eichner T., Weil T., Karnath T., Gutcaits A., Mahrhold S.,
RA   Sandhoff K., Proia R.L., Acharya K.R., Bigalke H., Binz T.;
RT   "Identification of the protein receptor binding site of botulinum
RT   neurotoxins B and G proves the double-receptor concept.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:359-364(2007).
RN   [20]
RP   FUNCTION (BOTULINUM NEUROTOXIN B HEAVY CHAIN), AND INTERACTION WITH HOST
RP   SV2 AND SYT1.
RX   PubMed=19476346; DOI=10.1021/bi9002138;
RA   Fu Z., Chen C., Barbieri J.T., Kim J.J., Baldwin M.R.;
RT   "Glycosylated SV2 and gangliosides as dual receptors for botulinum
RT   neurotoxin serotype F.";
RL   Biochemistry 48:5631-5641(2009).
RN   [21]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM NEUROTOXIN B HEAVY
RP   CHAIN), AND MUTAGENESIS OF LYS-1192 AND TRP-1262.
RX   PubMed=19650874; DOI=10.1111/j.1471-4159.2009.06298.x;
RA   Rummel A., Haefner K., Mahrhold S., Darashchonak N., Holt M., Jahn R.,
RA   Beermann S., Karnath T., Bigalke H., Binz T.;
RT   "Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding
RT   site prior to stimulation-dependent uptake with botulinum neurotoxin F
RT   utilising the three isoforms of SV2 as second receptor.";
RL   J. Neurochem. 110:1942-1954(2009).
RN   [22]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM NEUROTOXIN B HEAVY
RP   CHAIN), ACTIVITY REGULATION, SUBUNIT, AND SUBCELLULAR LOCATION.
RC   STRAIN=Type B;
RX   PubMed=21925111; DOI=10.1016/j.chom.2011.06.012;
RA   Sun S., Suresh S., Liu H., Tepp W.H., Johnson E.A., Edwardson J.M.,
RA   Chapman E.R.;
RT   "Receptor binding enables botulinum neurotoxin B to sense low pH for
RT   translocation channel assembly.";
RL   Cell Host Microbe 10:237-247(2011).
RN   [23]
RP   FUNCTION (BOTULINUM NEUROTOXIN TYPE B), AND SUBUNIT.
RC   STRAIN=Type B;
RX   PubMed=22720883; DOI=10.1021/bi3004928;
RA   Sun S., Tepp W.H., Johnson E.A., Chapman E.R.;
RT   "Botulinum neurotoxins B and E translocate at different rates and exhibit
RT   divergent responses to GT1b and low pH.";
RL   Biochemistry 51:5655-5662(2012).
RN   [24]
RP   FUNCTION (BOTULINUM NEUROTOXIN B LIGHT CHAIN), SUBSTRATE SPECIFICITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=22289120; DOI=10.1111/j.1348-0421.2012.00434.x;
RA   Yamamoto H., Ida T., Tsutsuki H., Mori M., Matsumoto T., Kohda T.,
RA   Mukamoto M., Goshima N., Kozaki S., Ihara H.;
RT   "Specificity of botulinum protease for human VAMP family proteins.";
RL   Microbiol. Immunol. 56:245-253(2012).
RN   [25]
RP   REVIEW.
RX   PubMed=28356439; DOI=10.1124/pr.116.012658;
RA   Pirazzini M., Rossetto O., Eleopra R., Montecucco C.;
RT   "Botulinum neurotoxins: Biology, pharmacology, and toxicology.";
RL   Pharmacol. Rev. 69:200-235(2017).
RN   [26] {ECO:0007744|PDB:1EPW, ECO:0007744|PDB:1F31}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-1291 IN COMPLEX WITH ZINC AND
RP   GANGLIOSIDE ANALOG, FUNCTION (BOTULINUM NEUROTOXIN B HEAVY CHAIN),
RP   COFACTOR, DOMAIN, AND GLYCAN-BINDING.
RX   PubMed=10932256; DOI=10.1038/78005;
RA   Swaminathan S., Eswaramoorthy S.;
RT   "Structural analysis of the catalytic and binding sites of Clostridium
RT   botulinum neurotoxin B.";
RL   Nat. Struct. Biol. 7:693-699(2000).
RN   [27] {ECO:0007744|PDB:2NM1}
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 858-1291 IN COMPLEX WITH SYT2
RP   RECEPTOR FRAGMENT, FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM
RP   NEUROTOXIN B HEAVY CHAIN), SUBUNIT, AND MUTAGENESIS OF VAL-1118; LYS-1192;
RP   PHE-1194; ALA-1196; SER-1199 AND PHE-1204.
RC   STRAIN=Type B;
RX   PubMed=17167421; DOI=10.1038/nature05387;
RA   Jin R., Rummel A., Binz T., Brunger A.T.;
RT   "Botulinum neurotoxin B recognizes its protein receptor with high affinity
RT   and specificity.";
RL   Nature 444:1092-1095(2006).
RN   [28] {ECO:0007744|PDB:2NP0}
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 2-1291 IN COMPLEX WITH ZINC AND
RP   SYT2 RECEPTOR FRAGMENT, FUNCTION (BOTULINUM NEUROTOXIN TYPE B AND BOTULINUM
RP   NEUROTOXIN B HEAVY CHAIN), COFACTOR, SUBUNIT, AND DISULFIDE BOND.
RX   PubMed=17167418; DOI=10.1038/nature05411;
RA   Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R.,
RA   Stevens R.C.;
RT   "Structural basis of cell surface receptor recognition by botulinum
RT   neurotoxin B.";
RL   Nature 444:1096-1100(2006).
RN   [29] {ECO:0007744|PDB:4KBB}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 857-1291 IN COMPLEX WITH
RP   CORECEPTORS SYT2 AND GANGLIOSIDE GD1A, FUNCTION (BOTULINUM NEUROTOXIN B
RP   HEAVY CHAIN), AND SUBUNIT.
RC   STRAIN=Okra / Type B1;
RX   PubMed=23807078; DOI=10.1038/ncomms3058;
RA   Berntsson R.P., Peng L., Dong M., Stenmark P.;
RT   "Structure of dual receptor binding to botulinum neurotoxin B.";
RL   Nat. Commun. 4:2058-2058(2013).
CC   -!- FUNCTION: [Botulinum neurotoxin type B]: Botulinum toxin causes flaccid
CC       paralysis by inhibiting neurotransmitter (acetylcholine) release from
CC       the presynaptic membranes of nerve terminals of the eukaryotic host
CC       skeletal and autonomic nervous system, with frequent heart or
CC       respiratory failure. Precursor of botulinum neurotoxin B which has 2
CC       coreceptors; complex polysialylated gangliosides found on neural tissue
CC       and specific membrane-anchored proteins found in synaptic vesicles
CC       (PubMed:17185412, PubMed:17167421, PubMed:17167418, PubMed:23807078).
CC       Receptor proteins are exposed on host presynaptic cell membrane during
CC       neurotransmitter release, when the toxin heavy chain (HC) binds to them
CC       (PubMed:14504267). Upon synaptic vesicle recycling the toxin is taken
CC       up via the endocytic pathway (PubMed:14504267). When the pH of the
CC       toxin-containing endosome drops a structural rearrangement occurs so
CC       that the N-terminus of the HC forms pores that allows the light chain
CC       (LC) to translocate into the cytosol (PubMed:3856850). Once in the
CC       cytosol the disulfide bond linking the 2 subunits is reduced and LC
CC       cleaves its target protein on synaptic vesicles, preventing their
CC       fusion with the cytoplasmic membrane and thus neurotransmitter release.
CC       Binds to host peripheral neuronal presynaptic membranes via
CC       synaptotagmins 1 and 2 (SYT1 and SYT2) (PubMed:8144634,
CC       PubMed:14504267). Toxin binds to the membrane proximal extra-
CC       cytoplasmic region of host SYT1 and SYT2 that is transiently exposed
CC       outside of cells during exocytosis; exogenous gangliosides enhance
CC       binding and subsequent uptake of toxin into host cells
CC       (PubMed:14504267, PubMed:15123599). Toxin uptake into neural cells
CC       requires stimulation (incubation with K(+) to stimulate SYT protein
CC       receptor exposure); subsequently the toxin colocalizes with its
CC       receptor in host cells with a concomitant decrease in target protein
CC       (synaptobrevin-2/VAMP2) immunoreactivity (PubMed:14504267). Toxin
CC       uptake can be blocked by the appropriate synaptotagmin protein
CC       fragments and gangliosides in cell culture and in mice
CC       (PubMed:14504267, PubMed:15123599). BoNT/B is a 'coincidence detector';
CC       it requires simultaneous binding to coreceptor GT1b and low pH to
CC       transform into a membrane-bound, oligomeric channel (PubMed:21925111,
CC       PubMed:22720883). Whole toxin only has protease activity after
CC       reduction which releases LC (PubMed:1331807, PubMed:7803399).
CC       {ECO:0000269|PubMed:1331807, ECO:0000269|PubMed:14504267,
CC       ECO:0000269|PubMed:15123599, ECO:0000269|PubMed:17167418,
CC       ECO:0000269|PubMed:17167421, ECO:0000269|PubMed:17185412,
CC       ECO:0000269|PubMed:21925111, ECO:0000269|PubMed:22720883,
CC       ECO:0000269|PubMed:23807078, ECO:0000269|PubMed:3856850,
CC       ECO:0000269|PubMed:7803399, ECO:0000269|PubMed:8144634}.
CC   -!- FUNCTION: [Botulinum neurotoxin B light chain]: Has proteolytic
CC       activity (PubMed:1331807). After translocation into the eukaryotic host
CC       cytosol, inhibits neurotransmitter release by acting as a zinc
CC       endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-
CC       2/VAMP2, blocking neurotransmitter release (PubMed:1331807,
CC       PubMed:7803399). In vitro the LC only has protease activity after
CC       reduction (PubMed:1331807, PubMed:7803399).
CC       {ECO:0000269|PubMed:1331807, ECO:0000305|PubMed:7803399}.
CC   -!- FUNCTION: [Botulinum neurotoxin B heavy chain]: Responsible for host
CC       epithelial cell transcytosis, host nerve cell targeting and
CC       translocation of light chain (LC) into host cytosol. Composed of 3
CC       subdomains; the translocation domain (TD), and N-terminus and C-
CC       terminus of the receptor-binding domain (RBD). The N-terminus of the TD
CC       wraps an extended belt around the perimeter of the LC; it does not seem
CC       to protect the active site, but might prevent premature LC dissociation
CC       from the translocation channel and protect toxin prior to translocation
CC       (PubMed:10932256, PubMed:17167418). Has 2 coreceptors; complex
CC       gangliosides found primarily on neural tissue and host synaptotagmin-1
CC       and -2 (SYT1 and SYT2) which bind simultaneously to adjacent but
CC       separate sites at the tip of the HC (PubMed:8144634, PubMed:17185412,
CC       PubMed:17167421, PubMed:17167418, PubMed:23807078). HC alone partially
CC       prevents uptake of whole toxin by neural cells, and delays paralysis
CC       onset by 160% (PubMed:10413679). Binding probably positions the TD for
CC       integration into the synaptic vesicle membrane (PubMed:17167418,
CC       PubMed:23807078). The HC forms channels at low pH that mediate
CC       transport of the light chain (LC) from the endocytic vesicle to the
CC       cytosol (PubMed:3856850). Binds gangliosides GD1b and GT1b
CC       (PubMed:10413679, PubMed:14731268). Gangliosides are not only a
CC       coreceptor, but also required for uptake into nerve cells
CC       (PubMed:21925111, PubMed:17167418). HC alone binds to host receptor
CC       proteins SYT1 and SYT2 (PubMed:14504267, PubMed:15123599,
CC       PubMed:17185412, PubMed:19650874). Interaction with SYT1 protein does
CC       not require SYT1 glycosylation (PubMed:19476346). The HC C-terminus
CC       (approximately residues 1079-1291) interacts with host SYT2
CC       (PubMed:15123599, PubMed:17167421, PubMed:17167418, PubMed:23807078).
CC       Has higher affinity for SYT2 than SYT1 (PubMed:17185412,
CC       PubMed:17167421). Significantly decreases uptake and toxicity of whole
CC       BoNT/B and BoNT/G (PubMed:19650874). {ECO:0000269|PubMed:10413679,
CC       ECO:0000269|PubMed:10932256, ECO:0000269|PubMed:14504267,
CC       ECO:0000269|PubMed:14731268, ECO:0000269|PubMed:15123599,
CC       ECO:0000269|PubMed:17167418, ECO:0000269|PubMed:17167421,
CC       ECO:0000269|PubMed:17185412, ECO:0000269|PubMed:19650874,
CC       ECO:0000269|PubMed:23807078, ECO:0000269|PubMed:8144634,
CC       ECO:0000305|PubMed:21925111, ECO:0000305|PubMed:3856850}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Limited hydrolysis of proteins of the neuroexocytosis
CC         apparatus, synaptobrevins, SNAP25 or syntaxin. No detected action on
CC         small molecule substrates.; EC=3.4.24.69;
CC         Evidence={ECO:0000269|PubMed:1331807};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:10932256, ECO:0000269|PubMed:1429690,
CC         ECO:0000269|PubMed:17167418};
CC       Note=Binds 1 zinc ion per subunit, to the LC (PubMed:1429690,
CC       PubMed:10932256, PubMed:17167418). {ECO:0000269|PubMed:10932256,
CC       ECO:0000269|PubMed:1429690, ECO:0000269|PubMed:17167418};
CC   -!- ACTIVITY REGULATION: Proteolysis inhibited by EDTA and captopril, and
CC       by peptides that encompass the VAMP2 cleavage site (Ala-Ser-Gln-Phe-
CC       Glu-Thr-Ser and Gln-Phe-Glu-Thr) (PubMed:1331807). Translocation of
CC       whole toxin into neurons is inhibited by toosendanin (PubMed:21925111).
CC       {ECO:0000269|PubMed:1331807, ECO:0000269|PubMed:21925111}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=19.2 uM for over-expressed human VAMP1
CC         {ECO:0000269|PubMed:22289120};
CC         KM=29.9 uM for over-expressed human VAMP2
CC         {ECO:0000269|PubMed:22289120};
CC         KM=11.6 uM for over-expressed human VAMP3
CC         {ECO:0000269|PubMed:22289120};
CC         Note=kcat is 3.96, 4.68 and 3.50 sec(-1) for over-expressed human
CC         VAMP1, VAMP2 and VAMP3 respectively. {ECO:0000269|PubMed:22289120};
CC   -!- SUBUNIT: Heterodimer; disulfide-linked heterodimer of a light chain
CC       (LC) and a heavy chain (HC) (PubMed:3139097, PubMed:1331807). At pH 4.4
CC       in the presence of ganglioside GT1b may form trimers (PubMed:21925111,
CC       PubMed:22720883). Interacts with host receptor synaptotagmin-1 (SYT1);
CC       interaction is improved in the presence of gangliosides
CC       (PubMed:8144634, PubMed:14504267, PubMed:19650874). Interacts with host
CC       receptor synaptotagmin-2 (SYT2) (PubMed:14504267, PubMed:15123599,
CC       PubMed:19650874, PubMed:17167421, PubMed:17167418, PubMed:23807078).
CC       SYT2 interaction and toxin uptake do not require gangliosides but are
CC       improved in their presence (PubMed:14504267, PubMed:15123599). HC
CC       interacts with a complex including at least host synaptic vesicle
CC       glycoprotein 2 (SV2) and synaptotagmin-1 (SYT1); copurification does
CC       not depend on glycosylation of either protein (PubMed:19476346).
CC       {ECO:0000269|PubMed:1331807, ECO:0000269|PubMed:14504267,
CC       ECO:0000269|PubMed:15123599, ECO:0000269|PubMed:17167418,
CC       ECO:0000269|PubMed:17167421, ECO:0000269|PubMed:19476346,
CC       ECO:0000269|PubMed:19650874, ECO:0000269|PubMed:21925111,
CC       ECO:0000269|PubMed:22720883, ECO:0000269|PubMed:23807078,
CC       ECO:0000269|PubMed:3139097, ECO:0000269|PubMed:8144634}.
CC   -!- INTERACTION:
CC       P10844; P29101: Syt2; Xeno; NbExp=6; IntAct=EBI-7661991, EBI-458017;
CC       P10844; P46097: Syt2; Xeno; NbExp=3; IntAct=EBI-7661991, EBI-457969;
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin type B]: Secreted
CC       {ECO:0000269|PubMed:3139097}. Host synapse, host presynaptic cell
CC       membrane {ECO:0000269|PubMed:14504267}. Note=Colocalizes with its SYT1
CC       receptor, probably in synaptic vesicles (PubMed:14504267). At pH 4.4 in
CC       the presence of ganglioside GT1b becomes a membrane-associated
CC       hydrophobic protein (PubMed:21925111). {ECO:0000269|PubMed:14504267,
CC       ECO:0000269|PubMed:21925111}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin B light chain]: Secreted
CC       {ECO:0000269|PubMed:3139097}. Host cytoplasm, host cytosol
CC       {ECO:0000305|PubMed:1331807, ECO:0000305|PubMed:8144634}.
CC   -!- SUBCELLULAR LOCATION: [Botulinum neurotoxin B heavy chain]: Secreted
CC       {ECO:0000269|PubMed:3139097}. Host synapse, host presynaptic cell
CC       membrane {ECO:0000269|PubMed:14504267}. Host cytoplasmic vesicle, host
CC       secretory vesicle, host synaptic vesicle membrane
CC       {ECO:0000305|PubMed:21925111}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- DOMAIN: [Botulinum neurotoxin B light chain]: Has protease activity
CC       (PubMed:1331807). {ECO:0000269|PubMed:1331807}.
CC   -!- DOMAIN: [Botulinum neurotoxin B heavy chain]: Has 3 functional domains;
CC       the translocation domain (TD) and the receptor-binding domain (RBD)
CC       which is further subdivided into N- and C-terminal domains (N-RBD and
CC       C-RBD) (PubMed:10932256). HC forms channels in bilayers at low pH
CC       (PubMed:3856850). The N-terminal belt of the TD wraps an extended belt
CC       around the perimeter of the LC; it is shorter than in BoNT/A and does
CC       not block the active site (PubMed:10932256). The belt may be a
CC       pseudosubstrate inhibitor which serves as an intramolecular chaperone
CC       for the LC prior to its translocation into the host cytosol
CC       (PubMed:17907800). {ECO:0000269|PubMed:10932256,
CC       ECO:0000269|PubMed:3856850, ECO:0000305|PubMed:17907800}.
CC   -!- PHARMACEUTICAL: Available under the name MYOBLOC (rimabotulinumtoxinB,
CC       US WorldMeds, LLC) for the treatment of adults with cervical dystonia.
CC   -!- MISCELLANEOUS: There are seven antigenically distinct forms of
CC       botulinum neurotoxin: Types A, B, C, D, E, F, and G; new subtypes are
CC       quite frequent.
CC   -!- MISCELLANEOUS: Botulism poisoning is usually food-borne, either by
CC       ingesting toxin or bacterial-contaminated food, or less frequently by
CC       inhalation poisoning. In both cases the neurotoxin binds to the apical
CC       surface of epithelial cells in the gut or airway. Toxin undergoes
CC       receptor-mediated endocytosis (using a different receptor than on
CC       target nerve cells), transcytosis across the epithelial cells and
CC       release into the general circulation. Once in the general circulation
CC       it binds to its target cells. {ECO:0000250|UniProtKB:P0DPI0}.
CC   -!- MISCELLANEOUS: Types A, B and E are the most frequent cause of adult
CC       human foodborne botulism; type A is the most severe, while type E has
CC       the shortest incubation period (PubMed:1431246).
CC       {ECO:0000269|PubMed:1431246}.
CC   -!- MISCELLANEOUS: Neurotoxin type B is released from bacteria mostly as a
CC       single chain and cleaved by host proteases into the active dichain
CC       (PubMed:4030755). {ECO:0000269|PubMed:4030755}.
CC   -!- SIMILARITY: Belongs to the peptidase M27 family. {ECO:0000305}.
CC   -!- CAUTION: A structure of a fragment of this protein in complex with the
CC       catalytic domain of C.botulinum neurotoxin type B (BoNT/B, botB) was
CC       reported; because of the lack of clear and continuous electron density
CC       for the VAMP2 peptide in the complex structure, the paper was
CC       retracted. One of its associated structures remains valid (PDB:1F82,
CC       light chain alone) (PubMed:10932255, PubMed:19578378).
CC       {ECO:0000269|PubMed:10932255, ECO:0000269|PubMed:19578378}.
CC   -!- WEB RESOURCE: Name=BotDB - A Database Resource for Clostridial
CC       Neurotoxins;
CC       URL="https://botdb.abcc.ncifcrf.gov/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M81186; AAA23211.1; -; Genomic_DNA.
DR   EMBL; Z11934; CAA77991.1; -; Genomic_DNA.
DR   EMBL; X70817; CAA50148.1; -; Genomic_DNA.
DR   PIR; A48940; A48940.
DR   RefSeq; WP_012291519.1; NZ_JACBEH010000008.1.
DR   PDB; 1EPW; X-ray; 1.90 A; A=2-1291.
DR   PDB; 1F31; X-ray; 2.60 A; A=2-1291.
DR   PDB; 1F82; X-ray; 2.20 A; A=2-425.
DR   PDB; 1G9A; X-ray; 2.10 A; A=2-1291.
DR   PDB; 1G9B; X-ray; 2.00 A; A=2-1291.
DR   PDB; 1G9C; X-ray; 2.35 A; A=2-1291.
DR   PDB; 1G9D; X-ray; 2.20 A; A=2-1291.
DR   PDB; 1I1E; X-ray; 2.50 A; A=2-1291.
DR   PDB; 1S0B; X-ray; 2.00 A; A=2-1291.
DR   PDB; 1S0C; X-ray; 2.20 A; A=2-1291.
DR   PDB; 1S0D; X-ray; 2.20 A; A=2-1291.
DR   PDB; 1S0E; X-ray; 1.90 A; A=2-1291.
DR   PDB; 1S0F; X-ray; 2.30 A; A=2-1291.
DR   PDB; 1S0G; X-ray; 2.60 A; A=2-1291.
DR   PDB; 1Z0H; X-ray; 2.00 A; A/B=854-1291.
DR   PDB; 2ETF; X-ray; 2.29 A; A/B=1-441.
DR   PDB; 2NM1; X-ray; 2.15 A; A=858-1291.
DR   PDB; 2NP0; X-ray; 2.62 A; A=2-1291.
DR   PDB; 2XHL; X-ray; 2.80 A; A=1-437, B=446-858.
DR   PDB; 3ZUQ; X-ray; 2.70 A; A=1-437, A=446-858.
DR   PDB; 4KBB; X-ray; 2.30 A; A/B=857-1291.
DR   PDB; 5VID; X-ray; 2.75 A; A/B/C/D/E=859-1291.
DR   PDB; 5VMR; X-ray; 1.95 A; A/B=859-1291.
DR   PDB; 6G5F; X-ray; 2.50 A; A/B=1-1291.
DR   PDB; 6G5G; X-ray; 2.00 A; A/B=1-1291.
DR   PDB; 6G5K; X-ray; 2.00 A; A/B=857-1291.
DR   PDB; 6QNS; X-ray; 2.40 A; A=857-1291.
DR   PDB; 6UC6; X-ray; 2.32 A; A/B=859-1291.
DR   PDB; 6UFT; X-ray; 2.90 A; A=859-1291.
DR   PDB; 6UHT; X-ray; 2.20 A; A/B=859-1291.
DR   PDB; 6UL4; X-ray; 3.18 A; A=859-1291.
DR   PDB; 7NA9; X-ray; 1.76 A; A=1-441.
DR   PDB; 7QFQ; EM; 3.60 A; A=1-1291.
DR   PDB; 7T5F; X-ray; 2.60 A; A/D=1-425.
DR   PDBsum; 1EPW; -.
DR   PDBsum; 1F31; -.
DR   PDBsum; 1F82; -.
DR   PDBsum; 1G9A; -.
DR   PDBsum; 1G9B; -.
DR   PDBsum; 1G9C; -.
DR   PDBsum; 1G9D; -.
DR   PDBsum; 1I1E; -.
DR   PDBsum; 1S0B; -.
DR   PDBsum; 1S0C; -.
DR   PDBsum; 1S0D; -.
DR   PDBsum; 1S0E; -.
DR   PDBsum; 1S0F; -.
DR   PDBsum; 1S0G; -.
DR   PDBsum; 1Z0H; -.
DR   PDBsum; 2ETF; -.
DR   PDBsum; 2NM1; -.
DR   PDBsum; 2NP0; -.
DR   PDBsum; 2XHL; -.
DR   PDBsum; 3ZUQ; -.
DR   PDBsum; 4KBB; -.
DR   PDBsum; 5VID; -.
DR   PDBsum; 5VMR; -.
DR   PDBsum; 6G5F; -.
DR   PDBsum; 6G5G; -.
DR   PDBsum; 6G5K; -.
DR   PDBsum; 6QNS; -.
DR   PDBsum; 6UC6; -.
DR   PDBsum; 6UFT; -.
DR   PDBsum; 6UHT; -.
DR   PDBsum; 6UL4; -.
DR   PDBsum; 7NA9; -.
DR   PDBsum; 7QFQ; -.
DR   PDBsum; 7T5F; -.
DR   AlphaFoldDB; P10844; -.
DR   SMR; P10844; -.
DR   DIP; DIP-42782N; -.
DR   IntAct; P10844; 4.
DR   MINT; P10844; -.
DR   BindingDB; P10844; -.
DR   ChEMBL; CHEMBL1075064; -.
DR   DrugBank; DB02379; Beta-D-Glucose.
DR   DrugBank; DB01705; Bis(5-Amidino-Benzimidazolyl)Methane.
DR   DrugBank; DB13903; Equine Botulinum Neurotoxin B Immune FAB2.
DR   DrugBank; DB03721; N-acetyl-alpha-neuraminic acid.
DR   MEROPS; M27.002; -.
DR   UniLectin; P10844; -.
DR   ABCD; P10844; 27 sequenced antibodies.
DR   BRENDA; 3.4.24.69; 1462.
DR   Reactome; R-HSA-5250958; Toxicity of botulinum toxin type B (botB).
DR   EvolutionaryTrace; P10844; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044161; C:host cell cytoplasmic vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0044164; C:host cell cytosol; IEA:UniProtKB-SubCell.
DR   GO; GO:0044156; C:host cell junction; IEA:UniProtKB-KW.
DR   GO; GO:0044231; C:host cell presynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008320; F:protein transmembrane transporter activity; EXP:Reactome.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:InterPro.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1120.10; -; 1.
DR   InterPro; IPR000395; Bot/tetX_LC.
DR   InterPro; IPR036248; Clostridium_toxin_transloc.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR011065; Kunitz_inhibitor_STI-like_sf.
DR   InterPro; IPR013104; Toxin_rcpt-bd_C.
DR   InterPro; IPR012928; Toxin_rcpt-bd_N.
DR   InterPro; IPR012500; Toxin_trans.
DR   Pfam; PF01742; Peptidase_M27; 1.
DR   Pfam; PF07951; Toxin_R_bind_C; 1.
DR   Pfam; PF07953; Toxin_R_bind_N; 1.
DR   Pfam; PF07952; Toxin_trans; 1.
DR   PRINTS; PR00760; BONTOXILYSIN.
DR   SUPFAM; SSF49899; SSF49899; 1.
DR   SUPFAM; SSF50386; SSF50386; 1.
DR   SUPFAM; SSF58091; SSF58091; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Direct protein sequencing; Disulfide bond;
KW   Host cell membrane; Host cytoplasm; Host cytoplasmic vesicle;
KW   Host membrane; Host synapse; Hydrolase; Lipid-binding; Membrane;
KW   Metal-binding; Metalloprotease; Neurotoxin; Pharmaceutical; Protease;
KW   Secreted; Toxin; Transmembrane; Virulence; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:3139097"
FT   CHAIN           2..1291
FT                   /note="Botulinum neurotoxin type B"
FT                   /id="PRO_0000444904"
FT   CHAIN           2..441
FT                   /note="Botulinum neurotoxin B light chain"
FT                   /id="PRO_0000029215"
FT   CHAIN           442..1291
FT                   /note="Botulinum neurotoxin B heavy chain"
FT                   /id="PRO_0000029216"
FT   REGION          442..857
FT                   /note="Translocation domain (TD)"
FT                   /evidence="ECO:0000250|UniProtKB:P0DPI0"
FT   REGION          481..532
FT                   /note="Belt; not required for channel formation"
FT                   /evidence="ECO:0000305|PubMed:10932256"
FT   REGION          858..1079
FT                   /note="N-terminus of receptor binding domain (N-RBD)"
FT                   /evidence="ECO:0000250|UniProtKB:P0DPI0"
FT   REGION          1080..1291
FT                   /note="C-terminus of receptor binding domain (C-RBD)"
FT                   /evidence="ECO:0000250|UniProtKB:P0DPI0"
FT   MOTIF           1260..1263
FT                   /note="Host ganglioside-binding motif"
FT                   /evidence="ECO:0000269|PubMed:10932256,
FT                   ECO:0000305|PubMed:14731268, ECO:0000305|PubMed:17185412"
FT   ACT_SITE        231
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         230
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095,
FT                   ECO:0000269|PubMed:10932256, ECO:0000305|PubMed:1429690,
FT                   ECO:0007744|PDB:1EPW, ECO:0007744|PDB:1F31,
FT                   ECO:0007744|PDB:2NP0"
FT   BINDING         234
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10095,
FT                   ECO:0000269|PubMed:10932256, ECO:0000305|PubMed:1429690,
FT                   ECO:0007744|PDB:1EPW, ECO:0007744|PDB:1F31,
FT                   ECO:0007744|PDB:2NP0"
FT   BINDING         268
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000269|PubMed:10932256,
FT                   ECO:0007744|PDB:1EPW, ECO:0007744|PDB:1F31,
FT                   ECO:0007744|PDB:2NP0"
FT   BINDING         1025
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /ligand_note="host ganglioside"
FT                   /evidence="ECO:0007744|PDB:4KBB"
FT   BINDING         1189..1190
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /ligand_note="host ganglioside"
FT                   /evidence="ECO:0000269|PubMed:10932256,
FT                   ECO:0000305|PubMed:14731268, ECO:0007744|PDB:4KBB"
FT   BINDING         1240..1241
FT                   /ligand="D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:4139"
FT                   /evidence="ECO:0000269|PubMed:10932256,
FT                   ECO:0000305|PubMed:14731268, ECO:0007744|PDB:4KBB"
FT   DISULFID        437..446
FT                   /note="Interchain (between light and heavy chains)"
FT                   /evidence="ECO:0000269|PubMed:10932256,
FT                   ECO:0000269|PubMed:17167418, ECO:0000305|PubMed:3139097,
FT                   ECO:0007744|PDB:1EPW, ECO:0007744|PDB:1F31,
FT                   ECO:0007744|PDB:2NP0"
FT   MUTAGEN         1118
FT                   /note="V->D: Greatly decreased binding of heavy chain (HC)
FT                   to host SYT2, whole toxin about 200-fold less toxic.
FT                   Significantly decreased binding of HC to host SYT1 and SYT2
FT                   independent of gangliosides; whole toxin about 100-fold
FT                   less toxic."
FT                   /evidence="ECO:0000269|PubMed:17167421,
FT                   ECO:0000269|PubMed:17185412"
FT   MUTAGEN         1183
FT                   /note="Y->R: Significantly decreased binding of heavy chain
FT                   to host SYT1 and SYT2 independent of gangliosides."
FT                   /evidence="ECO:0000269|PubMed:17185412"
FT   MUTAGEN         1189
FT                   /note="E->L: Decreased toxicity, heavy chain has decreased
FT                   binding to synaptosomes and to GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1190
FT                   /note="E->L: Greatly decreased toxicity, heavy chain has
FT                   decreased binding to synaptosomes, binds less GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1191
FT                   /note="E->L: Increased binding of heavy chain to host SYT1,
FT                   no effect on binding to SYT2 independent of gangliosides."
FT                   /evidence="ECO:0000269|PubMed:17185412"
FT   MUTAGEN         1192
FT                   /note="K->E: Greatly decreased binding of heavy chain to
FT                   host SYT2, whole toxin about dramatically less toxic.
FT                   Significantly decreased binding of heavy chain to host SYT1
FT                   and SYT2 independent of gangliosides; whole toxin
FT                   significantly less toxic. Essentially non-toxic; when
FT                   associated with L-1262. Heavy chain no longer inhibits
FT                   whole-toxin uptake and toxicity."
FT                   /evidence="ECO:0000269|PubMed:17167421,
FT                   ECO:0000269|PubMed:17185412, ECO:0000269|PubMed:19650874"
FT   MUTAGEN         1192
FT                   /note="K->M,Y: Decreased binding of heavy chain to host
FT                   SYT1 and SYT2 independent of gangliosides."
FT                   /evidence="ECO:0000269|PubMed:17185412"
FT   MUTAGEN         1194
FT                   /note="F->A: Greatly decreased binding of heavy chain to
FT                   host SYT2, whole toxin about 40-fold less toxic."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         1196
FT                   /note="A->K: Greatly decreased binding of heavy chain to
FT                   host SYT2, whole toxin about 1000-fold less toxic."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         1199
FT                   /note="S->Y: Increased binding of heavy chain to host SYT2,
FT                   no effect on toxicity."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         1204
FT                   /note="F->A: Greatly decreased binding of heavy chain to
FT                   host SYT2, whole toxin about 30-fold less toxic."
FT                   /evidence="ECO:0000269|PubMed:17167421"
FT   MUTAGEN         1241
FT                   /note="H->A: Decreased toxicity, heavy chain has decreased
FT                   binding to synaptosomes and to GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1241
FT                   /note="H->W: Greatly decreased toxicity, heavy chain has
FT                   decreased binding to synaptosomes and dramatic decrease in
FT                   GT1b binding."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1260
FT                   /note="S->A: Greatly decreased toxicity, heavy chain has
FT                   decreased binding to synaptosome and binds less GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1262
FT                   /note="W->L: Greatly decreased toxicity, heavy chain has
FT                   decreased binding to synaptosomes, heavy chain has dramatic
FT                   decrease in GT1b binding. Gangliosides no longer increase
FT                   heavy chain affinity for SYT1 or SYT2; whole toxin
FT                   significantly less toxic. Essentially non-toxic; when
FT                   associated with E-1192. Heavy chain no longer inhibits
FT                   whole-toxin uptake and toxicity. In mice without complex
FT                   gangliosides no change compared to wild-type protein."
FT                   /evidence="ECO:0000269|PubMed:14731268,
FT                   ECO:0000269|PubMed:17185412, ECO:0000269|PubMed:19650874"
FT   MUTAGEN         1263
FT                   /note="Y->F: Greatly decreased toxicity, heavy chain has
FT                   intermediate binding to synaptosomes, binds less GT1b."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   MUTAGEN         1263
FT                   /note="Y->S: Greatly decreased toxicity, heavy chain has
FT                   decreased binding to synaptosomes and dramatic decrease in
FT                   GT1b binding."
FT                   /evidence="ECO:0000269|PubMed:14731268"
FT   CONFLICT        30
FT                   /note="T -> M (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="R -> G (in Ref. 2; CAA77991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225
FT                   /note="A -> S (in Ref. 2; CAA77991)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        464
FT                   /note="S -> R (in Ref. 4; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          16..23
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           25..27
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   TURN            28..31
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          34..40
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          43..46
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           56..59
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          63..66
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          72..74
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   TURN            76..79
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           82..100
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           103..114
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:1G9D"
FT   TURN            134..136
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          137..142
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          145..147
FT                   /evidence="ECO:0007829|PDB:6G5G"
FT   STRAND          150..155
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          157..161
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          176..179
FT                   /evidence="ECO:0007829|PDB:1G9D"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          185..187
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          191..194
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          197..200
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          202..204
FT                   /evidence="ECO:0007829|PDB:6G5G"
FT   HELIX           207..209
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          210..212
FT                   /evidence="ECO:0007829|PDB:1S0E"
FT   HELIX           214..216
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           224..239
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           266..272
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           276..279
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           282..305
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          308..311
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           317..327
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          330..332
FT                   /evidence="ECO:0007829|PDB:1F82"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:1F82"
FT   HELIX           342..354
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           358..365
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          373..375
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          381..384
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   TURN            389..391
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   TURN            394..396
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           401..403
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           407..412
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   TURN            414..416
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   HELIX           418..420
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          421..423
FT                   /evidence="ECO:0007829|PDB:1S0E"
FT   HELIX           426..437
FT                   /evidence="ECO:0007829|PDB:7NA9"
FT   STRAND          446..450
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           451..453
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           460..462
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           466..468
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          471..473
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           488..493
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          495..498
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          506..508
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          524..531
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           537..542
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          554..557
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           559..564
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          568..570
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           575..581
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           587..606
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           607..609
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          610..612
FT                   /evidence="ECO:0007829|PDB:1G9B"
FT   HELIX           613..615
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          617..620
FT                   /evidence="ECO:0007829|PDB:1G9B"
FT   HELIX           624..628
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   TURN            631..635
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           639..646
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           647..651
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          666..668
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           675..707
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           709..738
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           743..747
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           753..786
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           788..812
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           814..817
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   TURN            819..824
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           825..831
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           840..842
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           847..857
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           860..863
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          864..870
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          872..877
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          879..881
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          884..887
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          891..893
FT                   /evidence="ECO:0007829|PDB:5VMR"
FT   STRAND          897..901
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          909..912
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   TURN            915..917
FT                   /evidence="ECO:0007829|PDB:6G5K"
FT   STRAND          918..923
FT                   /evidence="ECO:0007829|PDB:5VMR"
FT   STRAND          926..933
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           939..941
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           942..947
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          949..957
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          960..967
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          970..976
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          978..980
FT                   /evidence="ECO:0007829|PDB:1S0F"
FT   STRAND          982..988
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          991..995
FT                   /evidence="ECO:0007829|PDB:2NM1"
FT   STRAND          1003..1009
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1011..1018
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1021..1027
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1038..1047
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1054..1064
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           1068..1079
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1089..1091
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1093..1095
FT                   /evidence="ECO:0007829|PDB:1Z0H"
FT   STRAND          1097..1102
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           1103..1105
FT                   /evidence="ECO:0007829|PDB:1Z0H"
FT   STRAND          1108..1112
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1116..1123
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1145..1149
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1152..1154
FT                   /evidence="ECO:0007829|PDB:6QNS"
FT   STRAND          1158..1160
FT                   /evidence="ECO:0007829|PDB:6UL4"
FT   STRAND          1166..1173
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1176..1183
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1188..1192
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1194..1198
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1202..1205
FT                   /evidence="ECO:0007829|PDB:5VMR"
FT   STRAND          1208..1211
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1215..1217
FT                   /evidence="ECO:0007829|PDB:5VID"
FT   STRAND          1221..1231
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1234..1246
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1248..1250
FT                   /evidence="ECO:0007829|PDB:6G5G"
FT   STRAND          1251..1260
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   HELIX           1263..1266
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1269..1271
FT                   /evidence="ECO:0007829|PDB:1EPW"
FT   STRAND          1280..1283
FT                   /evidence="ECO:0007829|PDB:1EPW"
SQ   SEQUENCE   1291 AA;  150803 MW;  921DE5C518140DBD CRC64;
     MPVTINNFNY NDPIDNNNII MMEPPFARGT GRYYKAFKIT DRIWIIPERY TFGYKPEDFN
     KSSGIFNRDV CEYYDPDYLN TNDKKNIFLQ TMIKLFNRIK SKPLGEKLLE MIINGIPYLG
     DRRVPLEEFN TNIASVTVNK LISNPGEVER KKGIFANLII FGPGPVLNEN ETIDIGIQNH
     FASREGFGGI MQMKFCPEYV SVFNNVQENK GASIFNRRGY FSDPALILMH ELIHVLHGLY
     GIKVDDLPIV PNEKKFFMQS TDAIQAEELY TFGGQDPSII TPSTDKSIYD KVLQNFRGIV
     DRLNKVLVCI SDPNININIY KNKFKDKYKF VEDSEGKYSI DVESFDKLYK SLMFGFTETN
     IAENYKIKTR ASYFSDSLPP VKIKNLLDNE IYTIEEGFNI SDKDMEKEYR GQNKAINKQA
     YEEISKEHLA VYKIQMCKSV KAPGICIDVD NEDLFFIADK NSFSDDLSKN ERIEYNTQSN
     YIENDFPINE LILDTDLISK IELPSENTES LTDFNVDVPV YEKQPAIKKI FTDENTIFQY
     LYSQTFPLDI RDISLTSSFD DALLFSNKVY SFFSMDYIKT ANKVVEAGLF AGWVKQIVND
     FVIEANKSNT MDKIADISLI VPYIGLALNV GNETAKGNFE NAFEIAGASI LLEFIPELLI
     PVVGAFLLES YIDNKNKIIK TIDNALTKRN EKWSDMYGLI VAQWLSTVNT QFYTIKEGMY
     KALNYQAQAL EEIIKYRYNI YSEKEKSNIN IDFNDINSKL NEGINQAIDN INNFINGCSV
     SYLMKKMIPL AVEKLLDFDN TLKKNLLNYI DENKLYLIGS AEYEKSKVNK YLKTIMPFDL
     SIYTNDTILI EMFNKYNSEI LNNIILNLRY KDNNLIDLSG YGAKVEVYDG VELNDKNQFK
     LTSSANSKIR VTQNQNIIFN SVFLDFSVSF WIRIPKYKND GIQNYIHNEY TIINCMKNNS
     GWKISIRGNR IIWTLIDING KTKSVFFEYN IREDISEYIN RWFFVTITNN LNNAKIYING
     KLESNTDIKD IREVIANGEI IFKLDGDIDR TQFIWMKYFS IFNTELSQSN IEERYKIQSY
     SEYLKDFWGN PLMYNKEYYM FNAGNKNSYI KLKKDSPVGE ILTRSKYNQN SKYINYRDLY
     IGEKFIIRRK SNSQSINDDI VRKEDYIYLD FFNLNQEWRV YTYKYFKKEE EKLFLAPISD
     SDEFYNTIQI KEYDEQPTYS CQLLFKKDEE STDEIGLIGI HRFYESGIVF EEYKDYFCIS
     KWYLKEVKRK PYNLKLGCNW QFIPKDEGWT E
//
